Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Short-term Investments (2017 - 2025)

Puma Biotechnology's Short-term Investments history spans 9 years, with the latest figure at $67.9 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 113.86% year-over-year to $67.9 million; the TTM value through Dec 2025 reached $67.9 million, up 113.86%, while the annual FY2025 figure was $67.9 million, 113.86% up from the prior year.
  • Short-term Investments reached $67.9 million in Q4 2025 per PBYI's latest filing, up from $2.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $67.9 million in Q4 2025 to a low of $2.1 million in Q2 2025.
  • Average Short-term Investments over 5 years is $18.2 million, with a median of $11.4 million recorded in 2023.
  • Peak YoY movement for Short-term Investments: skyrocketed 812.42% in 2024, then crashed 92.96% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $8.8 million in 2021, then plummeted by 44.94% to $4.9 million in 2022, then soared by 133.0% to $11.4 million in 2023, then surged by 179.6% to $31.7 million in 2024, then soared by 113.86% to $67.9 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Short-term Investments are $67.9 million (Q4 2025), $2.1 million (Q3 2025), and $2.1 million (Q2 2025).